Topics
Glioblastoma | Treatment | Immunotherapy | Rivolumab
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Rivolumab
*Hendriksen JD, Locallo A, Maarup S, Debnath O, Ishaque N,
Hasselbach B, Skjøth-Rasmussen J, Yde CW, Poulsen HS,
Lassen U, Weischenfeldt J.
Immunotherapy
drives mesenchymal tumour cell state shift and TME immune response
in glioblastoma patients.
Neuro
Oncol. 2024 May 2:noae085. doi:
10.1093/neuonc/noae085. PMID:
38695342. Observational study˰
ˍ